What is Sanome?
Sanome is pioneering an IVD (In Vitro Diagnostics) innovation engine aimed at transforming the landscape of diagnostics development. The company's core mission involves the integration of diverse biomarkers to create engaging, accurate, and useful diagnostic products. These IVDs are designed to facilitate early disease detection and prevention, paving the way for novel healthcare delivery models and accessible at-home testing paradigms for a broad population.
How much funding has Sanome raised?
Sanome has raised a total of $2.7M across 1 funding round:
Unspecified
$2.7M
Unspecified (2021): $2.7M with participation from Selvedge Venture and Heal Capital
Key Investors in Sanome
Selvedge Venture
Selvedge Venture is an impact-focused venture capital firm specializing in early-stage startups within Biotechnology and Digital Technologies, particularly those addressing age-related diseases. They invest between Pre-Seed and Series A stages, aiming to alleviate healthcare burdens through innovative solutions.
Heal Capital
Heal Capital is a prominent European HealthTech and AI venture capital firm that invests EUR 1-5 million in mission-driven startups from Pre-Seed to Series A. They provide not only capital but also crucial access to the healthcare system for their portfolio companies.
What's next for Sanome?
The substantial enterprise-level funding, coupled with the recent strategic investment, positions Sanome for significant scaling and market penetration. This capital infusion is expected to accelerate the development and deployment of their IVD innovation engine, enabling broader access to advanced diagnostic tools. The company's focus on early detection and prevention aligns with global healthcare trends, suggesting a strategic expansion into new markets and therapeutic areas.
See full Sanome company page
